FOXO4-DRI

Description

Summary

In short: FOXO4-DRI is a synthetic peptide developed to disrupt a key survival mechanism in senescent cells (the FOXO4-p53 interaction), thereby triggering selective apoptosis of those cells in preclinical studies. It shows exciting potential in animal/cell models for age-related tissue dysfunction, but remains experimental and not ready for routine human use.

What is FOXO4-DRI?

• FOXO4 is a transcription factor, specifically FOXO4 (“forkhead box O4”). It plays roles in cell survival, stress responses, aging-related pathways, and interacts with other molecules like p53. Wikipedia+2PMC+2

• FOXO4-DRI is a synthetic cell-penetrating linear peptide designed to interfere with the interaction between FOXO4 and the tumor suppressor protein TP53 (p53). PMC+2Aging-US+2

• The “DRI” stands for D-retro-inverso: a peptide constructed with D-amino acids in a reversed sequence orientation, which often increases stability (resistance to degradation) relative to L-amino acid peptides. Core Peptides+1

How it works (mechanism of action)

• In senescent cells (cells that have stopped dividing but resist death and often secrete inflammatory factors), FOXO4 appears to help maintain survival by interacting with p53 and retaining p53 in the nucleus (or preventing its apoptotic actions). PMC+1

• FOXO4-DRI competes with or blocks the FOXO4:p53 interaction, causing p53 to become excluded from the nucleus in senescent cells, triggering apoptosis (programmed cell death) selectively in those senescent cells. PMC+1

• Because senescent cells accumulate with aging and contribute to tissue dysfunction via the “senescence-associated secretory phenotype” (SASP), the idea is that removing them can improve tissue health, reduce inflammation, and potentially ameliorate age-related decline. Aging-US

What research shows

• A landmark 2017 paper (“Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis …”) showed that in mice, treatment with a FOXO4-based peptide helped clear senescent cells and improved certain markers of aging/health. PMC

• In a 2020 study, aged male mice treated with FOXO4-DRI had improved testosterone secretion and better testicular microenvironment; the authors linked this to elimination of senescent Leydig cells. Aging-US+1

• In human chondrocyte (cartilage cell) studies: cells expanded in culture (which accumulate senescence) treated with FOXO4-DRI showed reduced senescent markers and improved profiles for implantation/reengineering.